Showing 441-450 of 606 results for "".
Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-14/23289/The Heat Is On. Updates on Physician Payment
https://practicaldermatology.com/topics/practice-management/the-heat-is-on-updates-on-physician-payment/23163/Here’s what to know about CMS’ physician payment rules for 2020.Kaposi Sarcoma in HIV-negative Men: A Case Series
https://practicaldermatology.com/youngmd-connect/resident-resource-center/kaposi-sarcoma-in-hiv-negative-men-a-case-series/23158/What Does Dermatology Need Right Now?
https://practicaldermatology.com/topics/practice-management/what-does-dermatology-need-right-now/23061/Experts weigh in on the pressing needs of the specialty today.Therapeutics Update
https://practicaldermatology.com/topics/psoriasis/therapeutics-update/20530/New products and pharmacologic developmentsCurrents
https://practicaldermatology.com/topics/practice-management/currents/20575/Aesthetic developments herald the dawn of a new age of rejuvenation.Are We All Clear?
https://practicaldermatology.com/topics/psoriasis/are-we-all-clear/20725/Understanding the safety of biologics for psoriasis in real-world settings.New Oral Agent May Shift Psoriasis Treatment Landscape
https://practicaldermatology.com/topics/psoriasis/new-oral-agent-may-shift-psoriasis-treatment-landscape/21258/A notable approval in 2014, apremilast may play an important role in bridging a wide gap in the care of moderate to severe psoriasis.Why Are Dermatologists Not Writing Biologics?
https://practicaldermatology.com/topics/practice-management/why-are-dermatologists-inoti-writing-biologics/23427/Biologics have been shown to be both safe and effective for a variety of indications, so why don’t more dermatologists prescribe them?2024 In Review: This Year's Trends in Dermatology
https://practicaldermatology.com/topics/feature/2024-review-years-trends-dermatology/29886/As the year comes to a close, Practical Dermatology asked Editorial Board members about trends from 2024—what was hot, what was not, new approvals that lived up to the hype, important new research, and other observations from the past year.